PURPOSE: To treat non-Hodgkin's B-cell lymphoma (B-NHL) in children with manageable toxicity-related morbidity and without any decrease in survival. PATIENTS AND METHODS: Between January 1998 and April 2003, 53 consecutive patients (age 16 years or less) from a single institution were enrolled. The patients were stratified by risk factors (stage and LDH level) and treated with a BFM 86/90 (Berlin-Frankfurt-Münster)-based protocol with reduction of the methotrexate dose from 5 mg/m to 2 mg/m. RESULTS: The mean age of the patients was 6 years (range 1-16 years). Seventy-two percent of the patients had lymphomas classified as Burkitt type, 11% as diffuse large cell lymphoma, and 6% as Burkitt-like lymphoma, and 11% were not classified. At a median follow-up of 35 months, 44 patients (83%) survived in complete remission. The event-free survival rate for all patients was 78% (SE = 0.07): 100% (SE = 0.0) for stage I/II patients and 74% (SE = 0.08) for stage III/IV patients. Six patients suffered initial treatment failure and one patient relapsed, all of whom died. There was only one death from sepsis related to treatment. CONCLUSIONS: This strategy was very effective for treating B-NHL in a developing country. The results were comparable to those of the BFM 90 study and other contemporary groups and represented an increase in the cure rates in childhood B-NHL in Brazil.
PURPOSE: To treat non-Hodgkin's B-cell lymphoma (B-NHL) in children with manageable toxicity-related morbidity and without any decrease in survival. PATIENTS AND METHODS: Between January 1998 and April 2003, 53 consecutive patients (age 16 years or less) from a single institution were enrolled. The patients were stratified by risk factors (stage and LDH level) and treated with a BFM 86/90 (Berlin-Frankfurt-Münster)-based protocol with reduction of the methotrexate dose from 5 mg/m to 2 mg/m. RESULTS: The mean age of the patients was 6 years (range 1-16 years). Seventy-two percent of the patients had lymphomas classified as Burkitt type, 11% as diffuse large cell lymphoma, and 6% as Burkitt-like lymphoma, and 11% were not classified. At a median follow-up of 35 months, 44 patients (83%) survived in complete remission. The event-free survival rate for all patients was 78% (SE = 0.07): 100% (SE = 0.0) for stage I/II patients and 74% (SE = 0.08) for stage III/IV patients. Six patients suffered initial treatment failure and one patient relapsed, all of whom died. There was only one death from sepsis related to treatment. CONCLUSIONS: This strategy was very effective for treating B-NHL in a developing country. The results were comparable to those of the BFM 90 study and other contemporary groups and represented an increase in the cure rates in childhood B-NHL in Brazil.
Authors: Mariana Tavares de Souza; Hasmik Mkrtchyan; Rocio Hassan; Daniela Ribeiro Ney-Garcia; Alice Maria Boulhosa de Azevedo; Elaine Sobral da Costa; Amanda Faria de Figueiredo; Thomas Liehr; Eliana Abdelhay; Maria Luiza Macedo Silva Journal: Int J Hematol Date: 2011-01-05 Impact factor: 2.490
Authors: Laila M Sherief; Usama R Elsafy; Elhamy R Abdelkhalek; Naglaa M Kamal; Doaa M Youssef; Rabab Elbehedy Journal: Mol Clin Oncol Date: 2014-09-24
Authors: Alex Sandro C Machado; Alexandre Gustavo Apa; Lidia Maria Magalhães de Rezende; Nívea Dias Amoêdo; Franklin David Rumjanek; Carlos E Bacchi; Claudete Esteves Klumb Journal: Clin Exp Med Date: 2008-07-11 Impact factor: 3.984
Authors: Carolina Minnicelli; Mário H M Barros; Claudete E Klumb; Sérgio O Romano; Ilana R Zalcberg; Rocio Hassan Journal: PLoS One Date: 2012-09-27 Impact factor: 3.240
Authors: Hugo A Martijn; Festus Njuguna; Gilbert Olbara; Sandra Langat; Jodi Skiles; Stephen Martin; Terry Vik; Peter M van de Ven; Gertjan Jl Kaspers; Saskia Mostert Journal: BMJ Paediatr Open Date: 2017-08-11